China Biologic Products Inc (NASDAQ:CBPO) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: October 11, 2016
Zacks Investment Research has downgraded China Biologic Products Inc (NASDAQ:CBPO) to Hold in a statement released on Tuesday October 11, 2016.
Previously on 10/10/2016, Zacks Investment Research released a statement for China Biologic Products Inc (NASDAQ:CBPO) upped the target price from $0.00 to $138.00. At the time, this indicated a possible upside of 0.12%.
Yesterday China Biologic Products Inc (NASDAQ:CBPO) traded -2.51% lower at $120.09. The company’s 50-day average is $119.42 and its two hundred day average is $117.26. The last close is up 2.41% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time. 168,361 shares of China Biologic Products Inc exchanged hands, down from an avg. volume of 219,703
Recent Performance Chart
With a market capitalization of $0, China Biologic Products Inc has PE ratio of 34.63 with a 52 week low of $95.70 and a 52 week high of $144.29 .
More About China Biologic Products Inc (NASDAQ:CBPO)
China Biologic Products, Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories. Its principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through approximately two subsidiaries, namely, Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co., Ltd. The Company also holds an interest in Xi'an Huitian Blood Products Co., Ltd., a plasma products company. Its products also include Human rabies immunoglobulin, Human tetanus immunoglobulin, Placenta polypeptide, Factor VIII and Human prothrombin complex concentrate.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.